Results of a three-year trial at Massachusetts General Hospital show that half of patients presenting with chest pain but at low or intermediate risk of acute coronary syndrome can be safely discharged following a negative 64-slice coronary CT evaluation.
Results of a three-year trial at Massachusetts General Hospital show that half of patients presenting with chest pain but at low or intermediate risk of acute coronary syndrome can be safely discharged following a negative 64-slice coronary CT evaluation.
The Rule-out Myocardial Infarction Using Computer-Assisted Tomography (ROMICAT) study prospectively evaluated 368 patients who underwent contrast-enhanced 64-slice coronary CT angiography after the determination of low or intermediate risk of ACS upon arrival in the emergency room of the Heart Center at MGH. Imaging investigated patients' coronary arteries for the presence of atherosclerotic plaque and significant (>50%) arterial stenosis.
Dr. Fabian Bamberg, an instructor in radiology in the MGH cardiac MR PET/CT program, reported Sunday at the 2008 RSNA meeting that nearly half of the patients had neither plaque nor stenosis. No patient with a negative coronary CTA assessment had a major coronary event in the six months after imaging, producing a negative predictive value of 100%.
Significant stenosis was identified in 18.4% of the patients, a finding that equated with more than an 11-fold increased risk of ACS, Bamberg said.
ROMICAT is the largest single-center trial to date to examine the feasibility of coronary CT to rule out acute coronary syndrome in the emergency room, Bamberg said. Studies presented in previous years at the RSNA conference were typically limited to about 100 patients.
"Our triage criteria really permit a safe discharge home," Bamberg said in an interview. "Patients are not required to be admitted to the hospital. They can be discharged right away."
Can MRI-Based AI Bolster Biopsy Decision-Making in PI-RADS 3 Cases?
December 9th 2024In patients with PI-RADS 3 lesion assessments, the combination of AI and prostate-specific antigen density (PSAD) level achieved a 78 percent sensitivity and 93 percent negative predictive value for clinically significant prostate cancer (csPCa), according to research presented at the Radiological Society of North American (RSNA) conference.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
RSNA 2020: Addressing Healthcare Disparities and Access to Care
December 4th 2020Rich Heller, M.D., with Radiology Partners, and Lucy Spalluto, M.D., with Vanderbilt University School of Medicine, discuss the highlights of their RSNA 2020 session on health disparities, focusing on the underlying factors and challenges radiologists face to providing greater access to care.
New Interventional Radiology Research Shows Merits of Genicular Artery Embolization for Knee OA
December 3rd 2024In a cohort of over 160 patients with knee osteoarthritis (OA), including grade 4 in nearly half of the cases, genicular artery embolization led to an 87 percent improvement in the quality of life index, according to research presented at the recent RSNA conference.
Siemens Healthineers Debuts New Photon-Counting CT Systems at RSNA
December 2nd 2024Debuting at the Radiological Society of North American (RSNA) conference, the new photon-counting computed tomography (PPCT) scanners Naeotom Alpha.Pro and Naeotom Alpha.Prime reportedly combine rapid scan times with high-resolution precision.